Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Five years later, what are the wider impacts of the US Supreme Court's Myriad decision on subject-matter eligibility and patent prosecution for nature-based products beyond isolated DNA?
New transparency policies have created a tension between the regulatory obligation to post clinical trials early and the desire to obtain patent protection.
Though a patent's protection scope should be based on the content of the claims and written description, determining the protection scope of a biosequence patent has always been a controversial issue in practice.
Life sciences company decision-makers can effectively manage disputes using appropriate dispute resolution techniques without resorting to expensive, complex, and uncertain litigation.
A landscape analysis of the recombinant factor VIII patent sector using network analysis to map the cooperation network among assignees shows emerging technologies that focus on improved methods for rFVIII production and bioactivity performance.
As universities and public research organizations increasingly partner with industry to fulfill their 'third mission' of innovation activities for economic and societal benefit, they have ethical obligations to ensure access to patented research tools, especially CRISPR–Cas9 technology.
General guidelines are presented on the types of patent protection available for inventions arising from research in the field of monoclonal antibodies, using concepts drawn from European case law and expert practice.
An examination of the prosecution and maintenance histories of approximately 2.7 million US patent applications indicates that women have less favorable outcomes than men.